42074-68-0

Basic information

• Product Name: 2-Chlorotritylchloride polymer resin
• Synonyms: Knorr 2-chlorotrityl resin rink amide 2-chlorotrityl resin;2,α-Dichlorobenzhydryl-polystyrene crosslinked with divinylbenzene;Diphenyl-2-chlorophenylMethyl Chloride;o-ChlorotriphenylchloroMethane;Chloro(2-chlorophenyl)diphenylmethane (2-Chlorophenyl)diphenylmethyl Chloride;ClotriMazole IMpurity C;(chloro(2-chlorophenyl)Methylene)dibenzene;Benzene,1-chloro-2-(chlorodiphenylMethyl)-
• CAS NO: 42074-68-0
• Molecular Formula: C₁₉H₁₄Cl₂
• Molecular Weight: 313.226
• EINECS: 255-647-3
• Product Categories: Biochemistry;Nucleosides, Nucleotides & Related Reagents;Protecting Agents for Hydroxyl and Amino Groups;Protecting Agents, Phosphorylating Agents & Condensing Agents;Protection & Derivatization Reagents (for Synthesis);Synthetic Organic Chemistry;Amino resin;(intermediate for clotrimazole);Resin and Derivatives
• Mol File: 42074-68-0.mol
• Article Data: 8

Chemical Properties

• Melting Point: 130-135 °C
• Boiling Point: 421.3 °C at 760 mmHg
• Flash Point: 194.2 °C
• Appearance: /Powder
• Density: 1.222 g/cm³
• Vapor Pressure: 6.44E-07mmHg at 25°C
• Refractive Index: 1.614
• Storage Temp.: 2-8°C
• Solubility: Soluble in Chloroform, methanol and dichloromethane, insoluble in water
• BRN: 1983914
• CAS DataBase Reference: 2-Chlorotritylchloride polymer resin(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Chlorotritylchloride polymer resin(42074-68-0)
• EPA Substance Registry System: 2-Chlorotritylchloride polymer resin(42074-68-0)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-24/25-22
• RIDADR: 3261
• WGK Germany: 3
• F: 10-21
• HazardClass: 8
• PackingGroup: III
• Hazardous Substances Data: 42074-68-0(Hazardous Substances Data)

Usage

Chemical Properties

off-white to yellow or brown beads

Uses

2-Chlorotrityl chloride is used as an intermediate of clotrimazole. It is also used in the preparation of modified trityl nucleosides as inhibitors of P. falciparum dUTPase. In addition, it serves as a protecting group reagent for carboxylic acids forming esters.

Application

2-Chlorotrityl Chloride is used in convergent peptide synthesis. Extremely acid labile resin for preparing peptide acids and partially protected peptide fragments by the Fmoc strategy. Cleavage can be effected by using AcOH/TFE/DCM or 0.5% TFA.

Preparation

2-Chlorotrityl chloride synthesis: It is esterified with 2-Chlorobenzoic acid and ethanol in the presence of sulfuric acid or p-toluenesulfonic acid to generate Ethyl 2-Chlorobenzoate, which is then condensed with phenylmagnesium bromide (Grignard reaction) to obtain (2-Chlorophenyl)diphenylmethanol magnesium salt is hydrolyzed with sulfuric acid to obtain (2-Chlorophenyl)diphenylmethanol, which is then chlorinated with thionyl chloride to obtain the product.

Biotechnological Applications

The 2-chlorotrityl chloride (2-CTC) resin is one of the most frequently used and most versatile resins for the large-scale manufacture of peptides. It is slightly less acid-labile than Trityl Resin and thus more widely used in solid phase peptide synthesis. Peptides UBI-8 and UBI-9 were synthesized by Fmoc-solid phase chemistry using a 2-chlorotrityl chloride linker-resin. Trityl linkers have certain advantages in comparison to the alkoxybenzyl alcohol (eg. Wang resin), especially in the area of peptide chemistry. First, the problem of racemization during the loading of the first amino acid (using DIPEA) is avoided with trityl linkers. Second, due to steric factors, no diketopiperazine formation is observed.

InChI:InChI=1/C19H14Cl2/c20-18-14-8-7-13-17(18)19(21,15-9-3-1-4-10-15)16-11-5-2-6-12-16/h1-14H

Upstream product

• 66774-02-5 o-chlorotriphenylmethanol 
• 2136-89-2 2-chlorobenzotrichloride 
• 71-43-2 benzene 
• 610-96-8 methyl chlorobenzoate 

Downstream Products

• 854220-15-8 1-(2-chloro-phenyl)-1,1-diphenyl-ethane 
• 5472-09-3 1-(2-chloro-phenyl)-1,1,2,2-tetraphenyl-ethane 
• 42074-69-1 Bisphenyl-o-chlorphenylcarbinylamin 
• 23593-75-1 clotrimazole 
• 87839-58-5 1-<(2-Chlorphenyl)diphenylmethyl>-4(1H)-pyridon 
• 87839-56-3 <(2-Chlorphenyl)diphenylmethyl>-2-pyridyl-ether 

Relevant articles and documents

Preparation method of clotrimazole

The invention provides a preparation method of clotrimazole. The preparation method comprises the following steps: step 1, chlorinating (2-chlorphenyl) diphenyl methanol into (2-chlorphenyl) diphenylchloromethane; 2, subjecting (2-chlorphenyl) diphenyl chloromethane and imidazole to condensation to form clotrimazole; the total reaction flow formula is shown in the specification. The invention provides a preparation method of clotrimazole. The initial raw materials (2-chlorphenyl) diphenyl methanol and imidazole are easy to obtain and stable in performance; reaction condition mildness, a product which is unstable when meeting water and synthesized in step 1 does not need to be separated and purified, and can be applied directly in step 2, not only are the requirements on equipment and operation reduced, but also the risk of influencing the quality of the raw material medicine is reduced; the preparation method is simple in operation, short in process period, high in product purity andsuitable for industrial production, , in addition, the reaction solvent in the step 1 is also the reaction solvent in the step 2, emission of three wastes is reduced, and environmental protection is better facilitated.

COMBINATORIAL ROSAMINE LIBRARY AND USES THEREOF

The present invention relates to a rosamine derivative compound, as described herein, having the following structure: Also disclosed are methods of making such compounds and for using them for detection and imaging.

Non-peptide inhibition of T-lymphocyte activation and therapies related thereto

Compounds, preparations and methods for immunosuppressive treatment of autoimmune disorders, graft rejection and/or graft/host disease. Therapeutically effective amounts of certain substituted triarylmethane compounds, such as 1-[(2-chlorophenyl)diphenylmethyl]-1H-pyrazole, are administered to mammalian patients to selectively inhibit the calcium-activated K + channel (IKCa1) in lymphocytes, monocytes, macrophages, platelets or endothelial cells without concomitant inhibition of P450-dependent enzyme systems, resulting in reduction of antigen-, cytokine-, or mitogen-induced calcium entry through store operated calcium channels in these cells, suppression of cytokine production by these cells, and inhibition of activation of these cells. Such inhibition of the Ca ++ activated K + channel (IKCa1) prevents the pre-Ca ++ stage of cell activation and thus causes immunosuppression and an anti-inflammatory response.